Submission of requests to JPMA (Japan Pharmaceutical Manufacturers Association) and JAMS (Japanese Association of Medical Sciences) on DOACs (NOACs); and receipt of replies from 5 companies and 3 relevant societies
2016-07-21
Medwatcher Japan received replies from five manufacturing/marketing companies of novel oral anticoagulants (DOACs or NOACs) and three relevant academic societies to its open letters sent them on March 2nd, 2016 regarding the conflict of interest issues with the “Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013)”.
Based on further issues found in these replies, Medwatcher Japan submitted requests to JPMA (Japan Pharmaceutical Manufacturers Association) and JAMS (Japanese Association of Medical Sciences) on July 21st, 2016.
- Related Documents And URL
-
- o Regarding for the information disclosure period with the “Transperency Guideline for the Relation between Corporate Activities and Medical Institutions” (attention to JPMA) (in Japanese)
- o Request on the Guidance of Qualification Standard to Participate in Practice Guideline Development (attention to JAMS) (in Japanese)
- o Sent an open letter on COI issues with “Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013)”
- o Replies from 3 academic societies (in Japanese)
- o Replies from 5 companies (in order of arrival) (in Japanese)
